CEA、NSE、CA125和TPA检测在小细胞肺癌中的临床表达

THE CLINICAL EXPRESSION OF CEA,NSE,CA125 AND TPA TEST IN SMALL CEIILUNG CANCER

目的:检测小细胞肺癌患者血清组织多肽特异性抗原(TPA)、神经元特异烯醇化酶(NSE)、癌抗原(CA125)和癌胚抗原(CEA)治疗前局限期、广泛期及治疗后不同预后情况的水平,为小细胞肺癌的临床诊断、病情监测提供新辅助手段。方法:用ELISA法检测结直肠癌患者血清TPA水平。用酶免法检测结直肠癌患者血清NSE、CA125和CEA水平。结果:血清TPA和NSE在局限期与广泛期差别有显著性意义(P<0.05),治疗后不同预后情况TPA和NSE浓度有显著性差异(P<0.01),NSE阳性率有显著性差异(P<0.01),各种组合检测中,TPA+NSE组和敏感性和约登指数最高。结论:血清TPA、NSE均可作为小细胞肺癌诊断、病情监测的临床指标,二者联合检测可提高其对小细胞肺癌临床应用价值。

Objective：To detect the different prognosis levels of serum TPA,NSE,CA125 and CEA of small cell lung cancer patients in before treatment limited stage,extensive stage and after treatment and provide new adjuvant option for the clinical diagnosis and disease monitoring of small cell lung cancer.Methods：Use ELISA to test serum TPA level of colorectal cancer patients.Use EIA to test serum NSE,CA125 and CEA levels of colorectal cancer patients.Results： Serum TPA and NSE in limited stage and extensive stage had significant difference（p〈0.05） and after treatment different prognosis thickness of TPA and NSE had significant difference（p〈0.01）.The positive rate of NSE had significant difference（p〈0.01）.Among all the combination tests,the sensitivity and Youden index in TPA＋NSE group were the highest.Conclusion： Serum TPA and NSE can both be taken as the diagnostic and diseasemonitoring clinical index for small cell lung cancer and the combination of the two can promote the clinical application value to small cell lung cancer.